• Bo Zhang, Zai-Bo Jiang, Ming-Sheng Huang, Kang-Shun Zhu, Shou-Hai Guan, and Hong Shan.
• Department of Radiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
• Urol. Int. 2013 Jan 1; 91 (3): 285-90.

ObjectiveTo evaluate the efficacy and safety of transarterial embolization (TAE) in the management of hematuria secondary to congenital renal arteriovenous malformations (AVM).Patients And MethodsBetween May 2007 and February 2012, 6 patients with congenital AVM treated with TAE were analyzed retrospectively, followed by a brief review of TAE in the treatment of congenital AVM. Clinical records with respect to general conditions, location, embolic materials, complications and overall outcome were collected from the original hospital charts and outpatient medical records.ResultsThree patients with AVM were confirmed by contrast-enhanced CT scans, and the other 3 patients were detected by renal angiography. TAE was performed with steel coils in 2 patients and n-butyl-2-cyanoacrylate (NBCA) in 4 patients. After a mean follow-up of 22 months, no serious adverse effects were observed in all patients. There were no complaints of hematuria at the end of the follow-up period.ConclusionFor unexplained massive hematuria, congenital renal AVM needs to be considered as a differential diagnosis. Selective renal angiography and embolization should be recommended as the first choice to treat massive hematuria secondary to congenital renal AVM.Copyright © 2013 S. Karger AG, Basel.

29 keywords...

hide…